NSC 364432

Drug Profile

NSC 364432

Alternative Names: 2-chloroethyl-3-sarcosinamide-1-nitrosourea; SarCNU; SarNU

Latest Information Update: 29 Mar 2010

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer National Cancer Institute (Canada)
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Alkylating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Colorectal cancer; Glioma

Most Recent Events

  • 06 May 2003 Phase-I clinical trials in Solid tumours in Canada (unspecified route)
  • 06 May 2003 A phase I study has been added to the pharmacokinetics and adverse events sections
  • 03 Feb 2000 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top